NEW YORK (GenomeWeb) – Novacyt and Cepheid have signed an agreement to introduce a complete human papillomavirus diagnostics system to Latin America.

Under the terms of the three-year, non-exclusive agreement, Cepheid will distribute Novacyt's NOVAprep vial, media, and cervical sample collection device in the region. These will be used in conjunction with the Cepheid Xpert HPV test, either as a primary cervical cancer screening assay or for reflex cytology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.